Final analysis of the randomized trial on imatinib as an adjuvant in localized gastrointestinal stromal tumors (GIST) from the EORTC Soft Tissue and Bone Sarcoma Group (STBSG), the Australasian Gastro-Intestinal Trials Group (AGITG), UNICANCER, French Sarcoma Group (FSG), Italian Sarcoma Group (ISG), and Spanish Group for Research on Sarcomas (GEIS)☆

Autor:	Casali, P.G.1,2 paolo.casali@istitutotumori.mi.it, Le Cesne, A.3, Velasco, A.P.4, Kotasek, D.5, Rutkowski, P.6, Hohenberger, P.7, Fumagalli, E.1,2, Judson, I.R.8, Italiano, A.8, Gelderblom, H.9, Penel, N.10, Hartmann, J.T.1,11, Duffaud, F.12, Goldstein, D.13, Martin-Broto, J.1,14, Gronchi, A.1, Wardelmann, E.15, Marréaud, S.16, Zalcberg, J.R.17, Litière, S.16
Zdroj:	Annals of Oncology. Apr2021, Vol. 32 Issue 4, p533-541. 9p.
Databáze:	Academic Search Ultimate
Externí odkaz:	Zobrazit plný text záznamu